Complete Cartesian Growth Corp. IV stock information by Barron's. View real-time CGCFU stock price and news, along with industry-best analysis.

Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell therapies using a drug delivery technology developed by the mRNA therapeutics ...

Cartesian Growth Corporation IV (the "Company") announced today the closing of its initial public offering of 27,500,000 units, including 2,500,000 units ...

Cartesian Therapeutics, Inc. RNAC announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FRISCO, Texas and LONDON, May 12, 2026 /PRNewswire/ — Bounteous, an AI services firm, today announced its acquisition of Cartesian, a specialist consulting firm focused on the global ...

Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused ...

Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, ...

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you ...

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical ...

Cartesian Growth Corporation IV (the 'Company”) announced today the pricing of its initial public offering of 25,000,000 units, at a price of $10.00 per unit. The units are expected to commence ...